July 2018

Through its Per-SVR study (pronounced “persevere”) the BC-CfE is conducting important research todetermine thresholds of prevention methods, such as harm reduction and safer sexual practices, to prevent hepatitis C reinfection among key populations. Per-SVR is a multi-year study observing people who have been successfully treated for hepatitis C virus (HCV) with direct acting antiretrovirals (DAAs).

Treatment as Prevention¨, pioneered by Director of the BC-CfE Dr. Julio Montaner, forms the foundation for an international movement to establish that undetectable equals untransmittable.